Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate
NCT03582475Phase 1Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jan 2019
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in small cell carcinoma of the bladder (SCCB), small cell carcinoma of the prostate (SCCP), neuroendocrine carcinoma of the prostate (NEPC) and 2 more, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Durable Response Rate at 6 months, Overall Response Rate at 3 years and 4 more. Started Jan 2019; status: active, not recruiting.
02
Drugs
03
Conditions
small cell carcinoma of the bladder (SCCB)small cell carcinoma of the prostate (SCCP)neuroendocrine carcinoma of the prostate (NEPC)Small cell carcinoma of the urethra (SCCU)small cell carcinoma of the ureter (PSCC)
Beyond the preview
Go deeper on NCT03582475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03582475.